These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38268787)

  • 1. Is eGFR Slope a Novel Predictor of Chronic Complications of Type 2 Diabetes Mellitus? A Systematic Review and Meta-Analysis.
    Sartore G; Ragazzi E; Deppieri E; Lapolla A
    J Diabetes Res; 2024; 2024():8859678. PubMed ID: 38268787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
    Helou N; Dwyer A; Shaha M; Zanchi A
    JBI Database System Rev Implement Rep; 2016 Jul; 14(7):169-207. PubMed ID: 27532796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline.
    Misra PS; Szeto SG; Krizova A; Gilbert RE; Yuen DA
    BMC Nephrol; 2020 Jul; 21(1):285. PubMed ID: 32682403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of prevalence, clinical profile, and predictors of rapid progression in diabetic kidney disease.
    Swaminathan SM; Bhojaraja MV; Attur RP; Nagri SK; Rao IR; Rangaswamy D; Shenoy SV; Nagaraju SP
    Ir J Med Sci; 2024 Apr; 193(2):1047-1054. PubMed ID: 37851330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney failure risk in type 1 vs. type 2 childhood-onset diabetes mellitus.
    Pleniceanu O; Twig G; Tzur D; Gruber N; Stern-Zimmer M; Afek A; Erlich T; Keinan-Boker L; Skorecki K; Calderon-Margalit R; Vivante A
    Pediatr Nephrol; 2021 Feb; 36(2):333-340. PubMed ID: 32761484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
    Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.
    Oshima M; Jun M; Ohkuma T; Toyama T; Wada T; Cooper ME; Hadjadj S; Hamet P; Harrap S; Mancia G; Marre M; Williams B; Chalmers J; Woodward M; Perkovic V;
    Diabetologia; 2019 Nov; 62(11):1988-1997. PubMed ID: 31302707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.
    Buyadaa O; Magliano DJ; Salim A; Koye DN; Shaw JE
    Diabetes Care; 2020 Jan; 43(1):122-129. PubMed ID: 31796570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-linear renal function decline is frequent in patients with type 2 diabetes who progress fast to end-stage renal disease and is associated with African-Caribbean ethnicity and HbA
    Stoilov SI; Fountoulakis N; Panagiotou A; Thomas S; Karalliedde J
    J Diabetes Complications; 2021 May; 35(5):107875. PubMed ID: 33736882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose targets for preventing diabetic kidney disease and its progression.
    Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term HbA1c variability and macro-/micro-vascular complications in type 2 diabetes mellitus: a meta-analysis update.
    Sartore G; Ragazzi E; Caprino R; Lapolla A
    Acta Diabetol; 2023 Jun; 60(6):721-738. PubMed ID: 36715767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
    Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
    Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes.
    Wada T; Haneda M; Furuichi K; Babazono T; Yokoyama H; Iseki K; Araki S; Ninomiya T; Hara S; Suzuki Y; Iwano M; Kusano E; Moriya T; Satoh H; Nakamura H; Shimizu M; Toyama T; Hara A; Makino H;
    Clin Exp Nephrol; 2014 Aug; 18(4):613-20. PubMed ID: 24132561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.